News and Announcements
Alcidion Executive Director Interview With FNN
- Published December 15, 2016 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
15th December 2016 – ASX Announcement
Alcidion Group Ltd (ASX: ALC) Executive Director, Nathan Buzza, presented an update to shareholders on the medical technology market, the benefits that hospitals and healthcare providers can expect from the company’s products and the company’s direction and goals, at the ASX and Finance News Network (FNN) CEO Sessions on 6 December 2016.
To view the interview please click on the button below.
About Alcidion Group
Alcidion is the brainchild of the former CEO of the SA Heath Department and Professor Malcolm Pradhan, a Stanford qualified physician. Over the past decade, Alcidion has invested $15m into the R&D of the cutting edge Clinical Decision Support System and is now focussed on commercializing the technology.
The introduction of Patient Protection & Affordable Care Act 2010 (“Obamacare”) requires US hospitals to accelerate the adoption of Electronic Medical Records. Alcidion is a leading supplier of these systems in Australia and is now seeking to expand its operations into the United States.
The company is backed by Allure Capital, the private investment vehicle of technology entrepreneur Mr. Nathan Buzza and BlueSky Private Equity (ASX:BLA). Mr Buzza was previously the second largest shareholder of Clinical Middleware Provider, Azure Healthcare (ASX:AZV), which catapulted into the spotlight after the stock rocketed from 3.3c to 34c over his two and a half year tenure.